DOCSLIB.ORG

Atlas Journal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atlas Journal Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 9, Number 1, Jan-Mar 2005 Previous Issue / Next Issue Genes CMKOR1 (2q37.3). Karin Broberg. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 1-5. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/CMKOR1ID40108ch2q37.html MAPRE1 (Microtubule-associated protein, RP/EB family, member 1) (20q11.1-11.23). Jennifer S Tirnauer. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 6-14. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/MAPRE1ID455ch20q11.html ERBB2 (erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) ) (17q11.2-q12). Patrizia Casalini, Marilena V Iorio. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 15-35. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/ERBB2ID162ch17q11.html TOP1 (topoisomerase (DNA) 1) (20q12-q13.1). Junko Horiguchi Yamada. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 36-41. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/TOP1ID320ch20q11.html WISP2 (Wnt-1-inducible signaling parthway protein-2) (20q12-13). Sushanta K. Banerjee, Snigdha Banerjee. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 42-47. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/WISP2ID42814ch20q12.html LHFP (lipoma HMGIC fusion partner) (13q12). Marleen Petit. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 48-51. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 2005; 1 I URL : http://AtlasGeneticsOncology.org/Genes/LHFPID248ch13q12.html TFPT (TCF3/E2A fusion partner) (19q13.4). Enrica Privitera, Andrea Biondi. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 52-55. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/TFPTID495ch19q13.html VAV1 (vav 1 oncogene) (19p13.2). Shulamit Katzav. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 56-62. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/VAV1ID195ch19p13.html Leukaemias del(13q) in ALL. David Betts. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 63-64. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/del13qALLID1188.html t(14;21)(q11;q22). Jacques Boyer. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 65-67. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t1421q11q22ID1180.html t(1;14)(q21;q32) IRTA1/IGH. Mary Callanan, Dominique Leroux. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 68-70. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0114q21q32ID1375.html t(1;6)(p35;p25). Jean loup Huret. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 71-72. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0106p35p25ID1378.html t(1;14)(q21;q32) MUC1/IGH. Jacques Boyer. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 73-75. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0114q21q32MUC1ID1342.html t(9;11)(q34;p15). Jean loup Huret. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 76-77. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0911q34p15ID1380.html t(X;20)(q13;q13.3). Kavita S. Reddy, Kathy Richkind. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 78-80. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 2005; 1 II URL : http://AtlasGeneticsOncology.org/Anomalies/t0X20q13q13ID1381.html t(16;21)(p11;q22) - updated. Jean Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 81-86. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t1621.html Solid Tumours Soft Tissue Tumors: Liposarcoma: Myxoid liposarcoma. Manuel Sánchez-Martín, Ines González-Herrero, Isidro Sánchez-Garcia. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 87-95. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/MyxoidLipoSarcID5169.html Uterus Tumours: an Overview. Roberta Vanni, Giuseppina Parodo. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 96-108. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/UterusTumOverviewID5157.html Soft Tissue Tumors: Low grade fibromyxoid sarcoma. Ioannis Panagopoulos, Fredrik Mertens, Nils Mandahl, Clelia Tiziana Storlazzi. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 109-113. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/LowGradFibromyxSarcID5185.html Soft Tissue Tumors: Soft Tissue Leiomyosarcoma. Jian-Hua Luo. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 114-116. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/SoftTisLeiomyoSarcID5122.html Soft tissue tumors: Lipoblastoma. Cristina Morerio, Claudio Panarello. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 117-120. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/LipoblastomaID5155.html t(16;21)(p11;q22) in Ewing tumours. Jean Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 121-126. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/t1621p11q22EwingID5329.html Cancer Prone Diseases LEOPARD syndrome. Maria Cristina Digilio. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 127-132. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/LeopardID10084.html Deep Insights Atlas Genet Cytogenet Oncol Haematol 2005; 1 III Some lessons from uniparental disomy (UDP) in the framework of comtemporary cytogenetics and molecular biology. Eric Engel. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 133-164. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Deep/UniparentDisomy2005ID20049.html Case Reports A new case of t(1;11)(q21;q23) in a child with M1 ANLL. Katell Le Du, Eric Jeandidier, Francine Garnache, Pierre Rohrlich, Jean-Luc Bresson, Marie- Agnès Collonge-Rame. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 165-168. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/0111CollongeID100008.html Translocation (X;20)(q13;q13.3): a nonrandom abnormality in four patients with myeloid disorders: case 1. Kavita S. Reddy, Kathy Richkind. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 169-171. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/0X20ReddyID100009.html Translocation (X;20)(q13;q13.3): case 2. Kavita S. Reddy, Kathy Richkind. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 172-174. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/0X20ReddyID100010.html Translocation (X;20)(q13;q13.3): case 3. Kavita S. Reddy, Kathy Richkind. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 175-177. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/0X20ReddyID100011.html Translocation (X;20)(q13;q13.3): case 4. Kavita S. Reddy, Kathy Richkind. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 178-180. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/0X20ReddyID100012.html Educational Items Genetics and Public Health. Anne-Marie Laberge. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 181-190. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Educ/GenetPublicHealthID30053ES.html Glossary of Medical and Molecular Genetics. Louis Dallaire. Atlas Genet Cytogenet Oncol Haematol 2005; 9 (1): 191-192. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Educ/GlossaryID30028ES.html © Atlas of Genetics and Cytogenetics in Oncology and Haematology Atlas Genet Cytogenet Oncol Haematol 2005; 1 IV X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching For comments and suggestions or contributions, please contact us [email protected]. Atlas Genet Cytogenet Oncol Haematol 2005; 1 V Atlas of Genetics and Cytogenetics in Oncology and Haematology CMKOR1 Identity Note RDC1 was originally thought to be the receptor for VIP. Other RDC1 names GPRN159 G protein-coupled receptor chemokine orphan receptor 1 G protein-coupled receptor RDC1 homolog Hugo CMKOR1 Location 2q37.3 Telomeric to IQCA Centromeric to COPS8 DNA/RNA Description The genomic size has been estimated to approximately 12.5-13.5 kb. RDC1 has previously been reported to contain only one exon of 1,09 kbp. However, the finding of a RDC1 transcript corresponding to four different regions with exon/intron boundaries in the BAC 514f21 suggests a more complex gene structure. The predicted amino acid sequence of exon 3 and 4 does not show any homology to the protein databases and, since they both contribute with stop codons, it could be questioned whether these sequences represent exons, or are part of an alternatively spliced 3' untranslated region of the gene. Pseudogene None Protein Description 362 amino acids; 41522 Da Expression RDC1 is expressed in embryological, juvenile as well as adult tissues. Expression has been reported in e.g. bladder, spleen, heart, skeletal muscle, peripheral nervous system and placenta. Localisation Integral membrane protein Function Orphan receptor, but its endogenous ligand has not yet been identified. The protein is also a coreceptor for human immunodeficiency viruses (HIV). RDC1 belongs to a family of G-protein coupled receptors, which includes hormone, neurotransmitter and light receptors, all of which transduce extracellular signals through interaction with guanine nucleotide (G) binding proteins. Atlas Genet Cytogenet Oncol Haematol 2005; 1 -1- Homology
Load more

Recommended publications
  • Oxidative Stress-Induced Chromosome Breaks Within
    Tan et al. Human Genomics (2018) 12:29 https://doi.org/10.1186/s40246-018-0160-8 PRIMARY RESEARCH Open Access Oxidative stress-induced chromosome breaks within the ABL gene: a model for chromosome rearrangement in nasopharyngeal carcinoma Sang-Nee Tan1, Sai-Peng Sim1* and Alan Soo-Beng Khoo2 Abstract Background: The mechanism underlying chromosome rearrangement in nasopharyngeal carcinoma (NPC) remains elusive. It is known that most of the aetiological factors of NPC trigger oxidative stress. Oxidative stress is a potent apoptotic inducer. During apoptosis, chromatin cleavage and DNA fragmentation occur. However, cells may undergo DNA repair and survive apoptosis. Non-homologous end joining (NHEJ) pathway has been known as the primary DNA repair system in human cells. The NHEJ process may repair DNA ends without any homology, although region of microhomology (a few nucleotides) is usually utilised by this DNA repair system. Cells that evade apoptosis via erroneous DNA repair may carry chromosomal aberration. Apoptotic nuclease was found to be associated with nuclear matrix during apoptosis. Matrix association region/scaffold attachment region (MAR/SAR) is the binding site of the chromosomal DNA loop structure to the nuclear matrix. When apoptotic nuclease is associated with nuclear matrix during apoptosis, it potentially cleaves at MAR/SAR. Cells that survive apoptosis via compromised DNA repair may carry chromosome rearrangement contributing to NPC tumourigenesis. The Abelson murine leukaemia (ABL) gene at 9q34 was targeted in this study as 9q34 is a common region of loss in NPC. This study aimed to identify the chromosome breakages and/or rearrangements in the ABL gene in cells undergoing oxidative stress-induced apoptosis.
    [Show full text]
  • Identifying the Optimal Gene and Gene Set in Hepatocellular Carcinoma Based on Differential Expression and Differential Co-Expression Algorithm
    1066 ONCOLOGY REPORTS 37: 1066-1074, 2017 Identifying the optimal gene and gene set in hepatocellular carcinoma based on differential expression and differential co-expression algorithm LI-YANG DONG1*, WEI-ZHONG ZHOU1*, JUN-WEI NI1, WEI XIANG1, WEN-HAO HU1, CHANG YU1 and HAI-YAN LI2 Departments of 1Invasive Technology and 2Rehabilitation, The First Affiliated Hospital of Wenzhou Medical University, Ouhai, Wenzhou, Zhejiang 325000, P.R. China Received June 23, 2016; Accepted August 10, 2016 DOI: 10.3892/or.2016.5333 * Abstract. The objective of this study was to identify the with ΔG = 18.681 and 24 HDE-HDC partitions in total. In optimal gene and gene set for hepatocellular carcinoma conclusion, we successfully investigated the optimal gene, (HCC) utilizing differential expression and differential MAPRE1, and gene set, nucleoside metabolic process, which co-expression (DEDC) algorithm. The DEDC algorithm may be potential biomarkers for targeted therapy and provide consisted of four parts: calculating differential expression significant insight for revealing the pathological mechanism (DE) by absolute t-value in t-statistics; computing differential underlying HCC. co-expression (DC) based on Z-test; determining optimal thresholds on the basis of Chi-squared (χ2) maximization and Introduction the corresponding gene was the optimal gene; and evaluating functional relevance of genes categorized into different Hepatocellular carcinoma (HCC) is the fifth most common partitions to determine the optimal gene set with highest mean cancer worldwide and the third leading cause of cancer-related * minimum functional information (FI) gain (ΔG). The optimal mortality (1), making it urgent to identify early diagnostic thresholds divided genes into four partitions, high DE and markers and therapeutic targets (2).
    [Show full text]
  • Location Analysis of Estrogen Receptor Target Promoters Reveals That
    Location analysis of estrogen receptor ␣ target promoters reveals that FOXA1 defines a domain of the estrogen response Jose´ e Laganie` re*†, Genevie` ve Deblois*, Ce´ line Lefebvre*, Alain R. Bataille‡, Franc¸ois Robert‡, and Vincent Gigue` re*†§ *Molecular Oncology Group, Departments of Medicine and Oncology, McGill University Health Centre, Montreal, QC, Canada H3A 1A1; †Department of Biochemistry, McGill University, Montreal, QC, Canada H3G 1Y6; and ‡Laboratory of Chromatin and Genomic Expression, Institut de Recherches Cliniques de Montre´al, Montreal, QC, Canada H2W 1R7 Communicated by Ronald M. Evans, The Salk Institute for Biological Studies, La Jolla, CA, July 1, 2005 (received for review June 3, 2005) Nuclear receptors can activate diverse biological pathways within general absence of large scale functional data linking these putative a target cell in response to their cognate ligands, but how this binding sites with gene expression in specific cell types. compartmentalization is achieved at the level of gene regulation is Recently, chromatin immunoprecipitation (ChIP) has been used poorly understood. We used a genome-wide analysis of promoter in combination with promoter or genomic DNA microarrays to occupancy by the estrogen receptor ␣ (ER␣) in MCF-7 cells to identify loci recognized by transcription factors in a genome-wide investigate the molecular mechanisms underlying the action of manner in mammalian cells (20–24). This technology, termed 17␤-estradiol (E2) in controlling the growth of breast cancer cells. ChIP-on-chip or location analysis, can therefore be used to deter- We identified 153 promoters bound by ER␣ in the presence of E2. mine the global gene expression program that characterize the Motif-finding algorithms demonstrated that the estrogen re- action of a nuclear receptor in response to its natural ligand.
    [Show full text]
  • Regulation of Neuronal Gene Expression and Survival by Basal NMDA Receptor Activity: a Role for Histone Deacetylase 4
    The Journal of Neuroscience, November 12, 2014 • 34(46):15327–15339 • 15327 Cellular/Molecular Regulation of Neuronal Gene Expression and Survival by Basal NMDA Receptor Activity: A Role for Histone Deacetylase 4 Yelin Chen,1 Yuanyuan Wang,1 Zora Modrusan,3 Morgan Sheng,1 and Joshua S. Kaminker1,2 Departments of 1Neuroscience, 2Bioinformatics and Computational Biology, and 3Molecular Biology, Genentech Inc., South San Francisco, California 94080 Neuronal gene expression is modulated by activity via calcium-permeable receptors such as NMDA receptors (NMDARs). While gene expression changes downstream of evoked NMDAR activity have been well studied, much less is known about gene expression changes that occur under conditions of basal neuronal activity. In mouse dissociated hippocampal neuronal cultures, we found that a broad NMDAR antagonist, AP5, induced robust gene expression changes under basal activity, but subtype-specific antagonists did not. While some of the gene expression changes are also known to be downstream of stimulated NMDAR activity, others appear specific to basal NMDARactivity.ThegenesalteredbyAP5treatmentofbasalcultureswereenrichedforpathwaysrelatedtoclassIIahistonedeacetylases (HDACs), apoptosis, and synapse-related signaling. Specifically, AP5 altered the expression of all three class IIa HDACs that are highly expressed in the brain, HDAC4, HDAC5, and HDAC9, and also induced nuclear accumulation of HDAC4. HDAC4 knockdown abolished a subset of the gene expression changes induced by AP5, and led to neuronal death under
    [Show full text]
  • Downloaded from [266]
    Patterns of DNA methylation on the human X chromosome and use in analyzing X-chromosome inactivation by Allison Marie Cotton B.Sc., The University of Guelph, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Medical Genetics) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2012 © Allison Marie Cotton, 2012 Abstract The process of X-chromosome inactivation achieves dosage compensation between mammalian males and females. In females one X chromosome is transcriptionally silenced through a variety of epigenetic modifications including DNA methylation. Most X-linked genes are subject to X-chromosome inactivation and only expressed from the active X chromosome. On the inactive X chromosome, the CpG island promoters of genes subject to X-chromosome inactivation are methylated in their promoter regions, while genes which escape from X- chromosome inactivation have unmethylated CpG island promoters on both the active and inactive X chromosomes. The first objective of this thesis was to determine if the DNA methylation of CpG island promoters could be used to accurately predict X chromosome inactivation status. The second objective was to use DNA methylation to predict X-chromosome inactivation status in a variety of tissues. A comparison of blood, muscle, kidney and neural tissues revealed tissue-specific X-chromosome inactivation, in which 12% of genes escaped from X-chromosome inactivation in some, but not all, tissues. X-linked DNA methylation analysis of placental tissues predicted four times higher escape from X-chromosome inactivation than in any other tissue. Despite the hypomethylation of repetitive elements on both the X chromosome and the autosomes, no changes were detected in the frequency or intensity of placental Cot-1 holes.
    [Show full text]
  • Role of RUNX1 in Aberrant Retinal Angiogenesis Jonathan D
    Page 1 of 25 Diabetes Identification of RUNX1 as a mediator of aberrant retinal angiogenesis Short Title: Role of RUNX1 in aberrant retinal angiogenesis Jonathan D. Lam,†1 Daniel J. Oh,†1 Lindsay L. Wong,1 Dhanesh Amarnani,1 Cindy Park- Windhol,1 Angie V. Sanchez,1 Jonathan Cardona-Velez,1,2 Declan McGuone,3 Anat O. Stemmer- Rachamimov,3 Dean Eliott,4 Diane R. Bielenberg,5 Tave van Zyl,4 Lishuang Shen,1 Xiaowu Gai,6 Patricia A. D’Amore*,1,7 Leo A. Kim*,1,4 Joseph F. Arboleda-Velasquez*1 Author affiliations: 1Schepens Eye Research Institute/Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, 20 Staniford St., Boston, MA 02114 2Universidad Pontificia Bolivariana, Medellin, Colombia, #68- a, Cq. 1 #68305, Medellín, Antioquia, Colombia 3C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 4Retina Service, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, 243 Charles St., Boston, MA 02114 5Vascular Biology Program, Boston Children’s Hospital, Department of Surgery, Harvard Medical School, 300 Longwood Ave., Boston, MA 02115 6Center for Personalized Medicine, Children’s Hospital Los Angeles, Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027, USA 7Department of Pathology, Harvard Medical School, 25 Shattuck St., Boston, MA 02115 Corresponding authors: Joseph F. Arboleda-Velasquez: [email protected] Ph: (617) 912-2517 Leo Kim: [email protected] Ph: (617) 912-2562 Patricia D’Amore: [email protected] Ph: (617) 912-2559 Fax: (617) 912-0128 20 Staniford St. Boston MA, 02114 † These authors contributed equally to this manuscript Word Count: 1905 Tables and Figures: 4 Diabetes Publish Ahead of Print, published online April 11, 2017 Diabetes Page 2 of 25 Abstract Proliferative diabetic retinopathy (PDR) is a common cause of blindness in the developed world’s working adult population, and affects those with type 1 and type 2 diabetes mellitus.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Subterranean Mammals Show Convergent Regression in Ocular Genes and Enhancers, Along with Adaptation to Tunneling
    RESEARCH ARTICLE Subterranean mammals show convergent regression in ocular genes and enhancers, along with adaptation to tunneling Raghavendran Partha1, Bharesh K Chauhan2,3, Zelia Ferreira1, Joseph D Robinson4, Kira Lathrop2,3, Ken K Nischal2,3, Maria Chikina1*, Nathan L Clark1* 1Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, United States; 2UPMC Eye Center, Children’s Hospital of Pittsburgh, Pittsburgh, United States; 3Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, United States; 4Department of Molecular and Cell Biology, University of California, Berkeley, United States Abstract The underground environment imposes unique demands on life that have led subterranean species to evolve specialized traits, many of which evolved convergently. We studied convergence in evolutionary rate in subterranean mammals in order to associate phenotypic evolution with specific genetic regions. We identified a strong excess of vision- and skin-related genes that changed at accelerated rates in the subterranean environment due to relaxed constraint and adaptive evolution. We also demonstrate that ocular-specific transcriptional enhancers were convergently accelerated, whereas enhancers active outside the eye were not. Furthermore, several uncharacterized genes and regulatory sequences demonstrated convergence and thus constitute novel candidate sequences for congenital ocular disorders. The strong evidence of convergence in these species indicates that evolution in this environment is recurrent and predictable and can be used to gain insights into phenotype–genotype relationships. DOI: https://doi.org/10.7554/eLife.25884.001 *For correspondence: [email protected] (MC); [email protected] (NLC) Competing interests: The Introduction authors declare that no The subterranean habitat has been colonized by numerous animal species for its shelter and unique competing interests exist.
    [Show full text]
  • Supplementary Figures and Tables
    SUPPLEMENTARY DATA Supplementary Figure 1. Isolation and culture of endothelial cells from surgical specimens of FVM. (A) Representative pre-surgical fundus photograph of a right eye exhibiting a FVM encroaching on the optic nerve (dashed line) causing tractional retinal detachment with blot hemorrhages throughout retina (arrow heads). (B) Magnetic beads (arrows) allow for separation and culturing of enriched cell populations from surgical specimens (scale bar = 100 μm). (C) Cultures of isolated cells stained positively for CD31 representing a successfully isolated enriched population (scale bar = 40 μm). ©2017 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1035/-/DC1 SUPPLEMENTARY DATA Supplementary Figure 2. Efficient siRNA knockdown of RUNX1 expression and function demonstrated by qRT-PCR, Western Blot, and scratch assay. (A) RUNX1 siRNA induced a 60% reduction of RUNX1 expression measured by qRT-PCR 48 hrs post-transfection whereas expression of RUNX2 and RUNX3, the two other mammalian RUNX orthologues, showed no significant changes, indicating specificity of our siRNA. Functional inhibition of Runx1 signaling was demonstrated by a 330% increase in insulin-like growth factor binding protein-3 (IGFBP3) RNA expression level, a known target of RUNX1 inhibition. Western blot demonstrated similar reduction in protein levels. (B) siRNA- 2’s effect on RUNX1 was validated by qRT-PCR and western blot, demonstrating a similar reduction in both RNA and protein. Scratch assay demonstrates functional inhibition of RUNX1 by siRNA-2. ns: not significant, * p < 0.05, *** p < 0.001 ©2017 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1035/-/DC1 SUPPLEMENTARY DATA Supplementary Table 1.
    [Show full text]
  • An Unconventional Interaction Between Dis1/TOG and Mal3/EB1 in Fission Yeast Promotes the Fidelity of Chromosome Segregation Yuzy Matsuo1,2, Sebastian P
    © 2016. Published by The Company of Biologists Ltd | Journal of Cell Science (2016) 129, 4592-4606 doi:10.1242/jcs.197533 RESEARCH ARTICLE An unconventional interaction between Dis1/TOG and Mal3/EB1 in fission yeast promotes the fidelity of chromosome segregation Yuzy Matsuo1,2, Sebastian P. Maurer1,3,4, Masashi Yukawa5, Silva Zakian6, Martin R. Singleton6, Thomas Surrey1,* and Takashi Toda2,5,* ABSTRACT (Mitchison and Kirschner, 1984). Such dynamic properties of Dynamic microtubule plus-ends interact with various intracellular MTs play an essential role in many cellular processes including target regions such as the cell cortex and the kinetochore. Two intracellular transport, cell polarity and cell division (Desai and conserved families of microtubule plus-end-tracking proteins, the Mitchison, 1997). MT dynamics are regulated by a cohort of XMAP215, ch-TOG or CKAP5 family and the end-binding 1 (EB1, evolutionarily conserved MT-associated proteins (MAPs) also known as MAPRE1) family, play pivotal roles in regulating (Akhmanova and Steinmetz, 2008). A subclass of MAPs, MT microtubule dynamics. Here, we study the functional interplay plus-end-tracking proteins (+TIPs) have unique properties, as they between fission yeast Dis1, a member of the XMAP215/TOG can specifically interact with the dynamic ends of MTs, thereby family, and Mal3, an EB1 protein. Using an in vitro microscopy playing a decisive role in determining the characteristics of MT assay, we find that purified Dis1 autonomously tracks growing plus-ends in cells (Buey et al., 2012; Duellberg et al., 2013). In microtubule ends and is a bona fide microtubule polymerase. Mal3 particular, end-binding 1 (EB1, also known as MAPRE1) and Xenopus Homo recruits additional Dis1 to microtubule ends, explaining the ch-TOG [known as XMAP215 ( ) and CKAP5 ( sapiens synergistic enhancement of microtubule dynamicity by these ); hereafter denoted TOG] are important +TIPs because they proteins.
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]